Title of Study:
Combination Therapy in Pulmonary Arterial Hypertension
Description:
An open label, non-comparative study design is appropriate for this Phase 4 study designed to assess whether a core therapy of bosentan, either as monotherapy or with the addition of sildenafil, enables patients with PAH to achieve a 6 MWD of ≥380 meters after 28 weeks of therapy. This design is also appropriate to pioneer the utility of cardiac MRI in assessing improved functional capacity in PAH and exploring its correlation with other parameters.
Contact:
Website for more information and study sites
Study End Date:
Expected September 2008
Study Sponsor:
Actelion Pharmaceuticals
